Oxford Outcomes provides specialist services in the areas of patient reported outcomes (PRO), health economics, epidemiology and translation and linguistic validation.
Elizabeth Thiele, former ICON executive vice president of Business Development, has been appointed president of this specialized service unit.
ICON CEO Peter Gray said the biopharmaceutical industry and regulators are more than ever before using post-marketing studies to demonstrate efficacy and safety, as well as demonstrating the economic value of products.
Oxford Outcomes group MD Paul Quarterman said blending the knowledge and expertise from both companies will lead to powerful, market-leading client solutions, both in the post-marketing arena and earlier in the development process.